GH Research PLC Ordinary Shares GHRS · Stock Open GH Research PLC Ordinary Shares in new tab
GH Research PLC Ordinary Shares Analysis (GHRS)
Is GH Research PLC Ordinary Shares a good investment? GH Research PLC Ordinary Shares (GHRS) is currently trading at 22.86 USD. Market analysts have a consensus price target of 42.89 USD. This suggests a potential upside from current levels.
Earnings Schedule: GH Research PLC Ordinary Shares is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -1.85.
Investor FAQ
Does GH Research PLC Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is GH Research PLC Ordinary Shares?
GH Research PLC Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.99.
Company Profile
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Community Discussion